Adjuvant chemo may benefit stage II obstructing colon cancer

  • Sabbagh C & al.
  • Ann Surg
  • 14 Feb 2020

  • curated by Jim Kling
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Adjuvant chemotherapy was associated with better OS and DFS in stage II obstructing colon cancer.

Why this matters

  • The study is the first to examine the association between adjuvant chemotherapy and outcomes specifically in stage II obstructing colon cancer.

Study design

  • Propensity-matched, retrospective, multicenter cohort study (n=504).
  • The researchers used an Average Treatment effect on the Treated (ATT) analysis, where treated patients had a weight of 1 and untreated patients had weights corresponding to their probability of receiving treatment.
  • Funding: None disclosed.

Key results

  • 35.5% of patients underwent adjuvant chemotherapy.
  • A multivariate analysis with ATT weighting and adjustment showed that treatment was associated with better OS (HR, 0.42; P=.0498) and better DFS (HR, 0.57; P=.0116).
  • When the analysis was limited to oxaliplatin-based regimens, adjuvant treatment was associated with improved OS (HR, 0.28; P=.0267) and a trend towards better DFS (HR, 0.63; P=.1016).

Limitations

  • Retrospective analysis.
  • No prestudy power calculation was performed.